Federal Supply Schedule 36F79720D0097

Award Date 3/15/20
Last Date to Order 3/14/30
Ultimate Awardee
Not listed
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
This Blanket Purchase Agreement was awarded by the Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 1 to Exosome Diagnostics, Inc. as a single award contract set aside for a sole source procurement. Over five years, Exosome Diagnostics, Inc. will provide an estimated 1,800 ExoDx Prostate Tests (Intelliscore), a non-invasive urine-based liquid biopsy test, at a value of $1,352,736. The test analyzes exosomal RNA to provide a patient-specific risk...
The U.S. Department of Veterans Affairs (VA) has awarded multiple federal contract Indefinite Delivery Vehicles (IDVs) to Mdxhealth, Inc., a for-profit healthcare company specializing in molecular diagnostic services. These IDVs, primarily Blanket Purchase Agreements (BPAs) issued under the VA's Medical Laboratory Testing and Analysis Services Federal Supply Schedule (FSS-621-II), enable the VA to efficiently procure a range of cancer screening and diagnostic testing services from Mdxhealth to...
The Department of Veterans Affairs (VA) Veterans Health Administration awarded a Blanket Purchase Agreement (BPA) to Mdxhealth, Inc., a for-profit healthcare company, for the provision of specialized cancer diagnostic testing services. The BPA is under the Medical Laboratory Testing and Analysis Services Federal Supply Schedule contract (FSS-621-II) and has a total potential value of $280,000 with an ultimate completion date of April 2, 2029. Specifically, the BPA covers DX Prostate Testing,...
Exact Sciences Corp, through its Exact Sciences Laboratories, LLC division, has been awarded a Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs' (VA) Veterans Integrated Service Network (VISN) 15 to provide Oncotype DX and other medical laboratory testing and analysis services. The BPA, valued up to $4 million, has a period of performance through August 2028. Exact Sciences has also been awarded several individual BPA calls under this overarching agreement, with ceiling...
The Department of Veterans Affairs (VA) has awarded Biodesix, Inc., a for-profit medical laboratory and diagnostic testing company based in Boulder, Colorado, a $20.3 million multiple-award Federal Supply Schedule contract for medical laboratory testing and analysis services. This contract enables VA medical centers to issue task orders for Biodesix's specialized lung testing capabilities, including Nodify lung blood testing, STX lung cancer screening, and other diagnostic testing options....
Biotheranostics Inc., a self-certified small disadvantaged business, has been awarded a Federal Supply Schedule contract (GS24F0019M) by the U.S. government to provide genomic diagnostic testing services to support precision oncology and cancer care. Under this multiple-award IDV, Biotheranostics has secured several delivery orders from the Department of Veterans Affairs (VA) and the Defense Health Agency (DHA) totaling over $700,000 between 2021-2023. The contracted services primarily involve...
This Blanket Purchase Agreement (BPA) was awarded by the Veterans Integrated Service Network 17 (VISN 17) of the Veterans Health Administration (VHA) to Exact Sciences Corporation, through its Exact Sciences Laboratories, LLC division. The BPA has a total ceiling value of $335,800 and is for the provision of Oncotype DX cancer testing services, including gene expression profiling and genomic testing, to support federal healthcare programs. The contract utilizes Exact Sciences' Federal Supply...
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 6 awarded a single award blanket purchase agreement to Exact Sciences Corporation for Oncotype DX laboratory testing services. The BPA was awarded on a sole source basis utilizing Exact's Federal Supply Schedule contract for medical laboratory testing and analysis services. The potential value of the BPA is $690,792 for a base period running from March 13, 2024 through March 12, 2029. A firm...
The U.S. Department of Veterans Affairs (VA), through its Veterans Integrated Service Network (VISN) 19, has awarded a series of Blanket Purchase Agreement (BPA) call contracts to Mdxhealth, Inc., a for-profit healthcare company specializing in molecular diagnostic services and cancer testing. The contracts, valued at over $500,000 total, are for the provision of MDX health testing and analysis services to support the VA's healthcare programs for veterans. The contracts were awarded under the...
This federal contract IDV is a Blanket Purchase Agreement (BPA) awarded by the Veterans Integrated Service Network 17 (VISN 17) of the Department of Veterans Affairs (VA) to Mdxhealth, Inc., a for-profit healthcare company that provides molecular diagnostic services. The BPA, issued under Mdxhealth's existing General Services Administration (GSA) Federal Supply Schedule contract for Medical Laboratory Testing and Analysis Services, has a ceiling value of $320,000 and a period of performance...

Exosome Diagnostics Inc., a subsidiary of Bio-Techne Corporation, has been awarded a $1,400,000 Federal Supply Schedule contract under GSA Schedule 621-II for Medical Laboratory Testing and Analysis Services. This multiple-award Indefinite Delivery Vehicle (IDV) enables various Department of Veterans Affairs (VA) Veterans Integrated Service Networks (VISNs) to access Exosome Diagnostics' specialized liquid biopsy testing services, primarily the ExoDx Prostate (IntelliScore) test.

The ExoDx Prostate IntelliScore is a non-invasive, urine-based liquid biopsy that analyzes exosomal RNA biomarkers to assess the risk of clinically significant prostate cancer in men considering an initial biopsy. Exosome Diagnostics has received multiple delivery orders from different VA networks, totaling over $1.2 million, to provide this testing service as part of the VA's prostate cancer screening initiatives for veterans. Additionally, the company holds a $1,352,736 Blanket Purchase Agreement with VA VISN 1 to deliver approximately 1,800 ExoDx Prostate Tests annually to support non-invasive prostate cancer screening. These contracts, which have no set-aside designations, demonstrate Exosome Diagnostics' significant role in supplying advanced diagnostic solutions to federal healthcare programs.

Generated 3/4/25, 11:11 AM